25 May 2013
Keywords: hybridon, antisense, trials, imminent, specialist, awaiting, approval
Article | 08 February 1993
US antisense specialist Hybridon is awaiting approval from the US Food
and Drug Administration and expects to begin clinical trials ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
24 May 2013
© 2013 thepharmaletter.com